JPWO2008078589A1 - 放射性ハロゲン標識有機化合物の前駆体化合物の製造方法 - Google Patents
放射性ハロゲン標識有機化合物の前駆体化合物の製造方法 Download PDFInfo
- Publication number
- JPWO2008078589A1 JPWO2008078589A1 JP2008551038A JP2008551038A JPWO2008078589A1 JP WO2008078589 A1 JPWO2008078589 A1 JP WO2008078589A1 JP 2008551038 A JP2008551038 A JP 2008551038A JP 2008551038 A JP2008551038 A JP 2008551038A JP WO2008078589 A1 JPWO2008078589 A1 JP WO2008078589A1
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- sulfonic acid
- carbon atoms
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 52
- 239000002243 precursor Substances 0.000 title claims abstract description 21
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 150000002894 organic compounds Chemical class 0.000 title claims description 4
- 229910052736 halogen Inorganic materials 0.000 title description 2
- 150000002367 halogens Chemical class 0.000 title description 2
- 238000006243 chemical reaction Methods 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 34
- -1 nitrogen-containing heterocyclic compounds Chemical class 0.000 claims abstract description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 25
- 238000000746 purification Methods 0.000 claims abstract description 15
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 12
- 239000011737 fluorine Substances 0.000 claims abstract description 12
- 150000003973 alkyl amines Chemical group 0.000 claims abstract description 7
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims abstract 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 125000006239 protecting group Chemical group 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 4
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 claims description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 2
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical group CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 claims description 2
- WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 claims description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims description 2
- HWTDMFJYBAURQR-UHFFFAOYSA-N 80-82-0 Chemical compound OS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O HWTDMFJYBAURQR-UHFFFAOYSA-N 0.000 claims description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- 229940043279 diisopropylamine Drugs 0.000 claims description 2
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 claims description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims description 2
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 claims description 2
- 238000007613 slurry method Methods 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims 1
- 229940027541 fluciclovine f-18 Drugs 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 12
- NTEDWGYJNHZKQW-DGMDOPGDSA-N fluciclovine ((18)F) Chemical compound OC(=O)[C@]1(N)C[C@H]([18F])C1 NTEDWGYJNHZKQW-DGMDOPGDSA-N 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000002904 solvent Substances 0.000 description 15
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- NTEDWGYJNHZKQW-KWCOIAHCSA-N 1-amino-3-fluoranylcyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(N)CC([18F])C1 NTEDWGYJNHZKQW-KWCOIAHCSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000002372 labelling Methods 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000002194 synthesizing effect Effects 0.000 description 9
- QIBHSXMRVAAKPX-UHFFFAOYSA-N 1-azaniumyl-3-phenylmethoxycyclobutane-1-carboxylate Chemical compound C1C(N)(C(O)=O)CC1OCC1=CC=CC=C1 QIBHSXMRVAAKPX-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 229940091173 hydantoin Drugs 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 5
- 239000012217 radiopharmaceutical Substances 0.000 description 5
- 229940121896 radiopharmaceutical Drugs 0.000 description 5
- 230000002799 radiopharmaceutical effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- ZZSFCRFLCCLRFG-UHFFFAOYSA-N ethyl 1-amino-3-phenylmethoxycyclobutane-1-carboxylate Chemical compound C1C(C(=O)OCC)(N)CC1OCC1=CC=CC=C1 ZZSFCRFLCCLRFG-UHFFFAOYSA-N 0.000 description 4
- YCSWTNOOIHXDLP-UHFFFAOYSA-N ethyl 3-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutane-1-carboxylate Chemical compound CC(C)(C)OC(=O)NC1(C(=O)OCC)CC(O)C1 YCSWTNOOIHXDLP-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KAOJAYKTZHRBIJ-UHFFFAOYSA-N cyclobutyloxymethylbenzene Chemical compound C=1C=CC=CC=1COC1CCC1 KAOJAYKTZHRBIJ-UHFFFAOYSA-N 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- NMKOOYIJFNHFEK-UHFFFAOYSA-N ethyl 1-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylmethoxycyclobutane-1-carboxylate Chemical compound C1C(C(=O)OCC)(NC(=O)OC(C)(C)C)CC1OCC1=CC=CC=C1 NMKOOYIJFNHFEK-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical class [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000007257 deesterification reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000005949 ethanesulfonyloxy group Chemical group 0.000 description 2
- SMVBADCAMQOTOV-UHFFFAOYSA-N ethyl cyclobutanecarboxylate Chemical compound CCOC(=O)C1CCC1 SMVBADCAMQOTOV-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- IZNUNQINHLLGGU-UHFFFAOYSA-N 1-amino-3-fluorocyclohexane-1-carboxylic acid Chemical compound OC(=O)C1(N)CCCC(F)C1 IZNUNQINHLLGGU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108050005273 Amino acid transporters Proteins 0.000 description 1
- 102000034263 Amino acid transporters Human genes 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical class ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical group NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- UDCZUKYPQKTAGD-UHFFFAOYSA-N ethyl 1-hydroxycyclobutane-1-carboxylate Chemical compound CCOC(=O)C1(O)CCC1 UDCZUKYPQKTAGD-UHFFFAOYSA-N 0.000 description 1
- HXIXVACPUCDUBU-UHFFFAOYSA-N ethyl 3-fluoro-1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutane-1-carboxylate Chemical compound CC(C)(C)OC(=O)NC1(C(=O)OCC)CC(F)C1 HXIXVACPUCDUBU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VLAPMBHFAWRUQP-UHFFFAOYSA-L molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical group N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21H—OBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION
- G21H5/00—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for
- G21H5/02—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for as tracers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
- C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/42—Separation; Purification; Stabilisation; Use of additives
- C07C303/44—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01T—MEASUREMENT OF NUCLEAR OR X-RADIATION
- G01T1/00—Measuring X-radiation, gamma radiation, corpuscular radiation, or cosmic radiation
- G01T1/16—Measuring radiation intensity
- G01T1/161—Applications in the field of nuclear medicine, e.g. in vivo counting
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- High Energy & Nuclear Physics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
保護体・・・FACBCのアミノ基およびカルボキシル基を保護した化合物
OH体・・・保護体の18Fを導入する位置にOH基を導入した化合物
脱離基付加体・・・OH体のOH基に脱離基を導入した化合物
前記反応工程が終了した後に前記反応溶液を精製して、下記式(2):
を含むことを特徴とする。
ここで、反応液に加える塩基は、反応時に発生する塩酸をトラップできるものであればよく、好ましくはトリエチルアミンを用いることができる。また、用いる量は、塩化チオニルに対し等量以上とする。
塩化チオニルの量は、反応原料である1−アミノ−3−ベンジルオキシシクロブタン−1−カルボン酸に対して等量以上である必要がある。このとき、塩化チオニルの量が少ないと、エチルエステル化反応が十分に進行しないため、好ましくない。また、添加量が多すぎると、より過剰な塩酸が発生し、より多くの塩基を用いる必要が生じるため好ましくない。好ましい態様において、塩化チオニルの量は、1−アミノ−3−ベンジルオキシシクロブタン−1−カルボン酸に対して、5当量以下とする。
この操作により、1−(N−(t−ブトキシカルボニル)アミノ)−3−ベンジルオキシ−シクロブタン−1−カルボン酸エチルエステルを得ることができる。
最後に、この反応溶液を精製することにより、目的物であるsyn−1−(N−(t−ブトキシカルボニル)アミノ)−3−[((トリフルオロメチル)スルフォニル)オキシ]−シクロブタン−1−カルボン酸エチルエステルを実質的に単一の立体異性体として得ることができる。好ましい精製方法としては、反応溶液に、水、エーテル等の有機溶媒及び酸を加え、有機層を精製する分液精製法を用いることができる。
anti−[18F]−FACBCの合成は、前駆体に放射性フッ素を付加する工程、及び、放射性フッ素を付加した化合物につき脱保護を行う工程の、2段階の工程にて行われる。
5−(3−ベンジルオキシシクロブタン)ヒダントイン6.15g(25mmol相当)に、飽和水酸化バリウム水溶液250mLを加え、114℃の油浴にて24時間以上加熱還流(reflux)して反応させ、1−アミノ−3−ベンジルオキシシクロブタン−1−カルボン酸を合成した。クロロホルム:メタノール=5:1(syn−ヒダントインのRf値=0.6付近)及びクロロホルム:メタノール=95:1(syn−ヒダントインのRf値=0.3付近)の2種類の系を展開溶媒として使用したTLC分析を行い、反応終了の確認を行った(UVとリンモリブデン酸による呈色によって確認)。なお、反応に使用したヒダントインのsyn/anti比は、約65/35であった。
充分に乾燥させ水分を取り除いた1−アミノ−3−ベンジルオキシシクロブタン−1−カルボン酸19.07gを、エタノール250mLに溶解させた。この液に、トリエチルアミン9.5mL(75mmol相当)を加え、−78℃にて20分間冷却し、塩化チオニル4.6mL(62.5mmol相当)を加えた。反応液を、0℃で1時間、室温で1時間それぞれ攪拌した後、95℃の油浴にて、1晩加熱還流した。クロロホルム:メタノール=95:1(目的物のRf値=0.6付近)を展開溶媒として使用したTLC分析(UVとリンモリブデン酸による呈色にて確認)により、反応終了の確認を行った。反応終了確認後、反応液を減圧濃縮して1−アミノ−3−ベンジルオキシシクロブタン−1−カルボン酸エチルエステルを得た。
1−アミノ−3−ベンジルオキシシクロブタン−1−カルボン酸エチルエステル7.64gを、エタノール:トリエチルアミン=9:1混液250mLに溶解させた。この溶液を氷浴で15分冷却した後、二炭酸ジ−t−ブチル8.6mL(37.5mmol相当)を加え、室温下1晩攪拌した。ヘキサン:酢酸エチル=1:1(反応目的物のRf値=0.6付近)を展開溶媒として使用したTLC(UV及びモリブデン酸による呈色にて確認)にて、反応終了を確認した。反応終了確認後、反応液を減圧濃縮し、残渣として白色結晶を得た。この残渣に、冷酢酸エチル150mLと0.5mol/Lの冷塩酸150mLを加え、氷浴下で5分攪拌し、次いで室温にて静置分離した。有機層を水150mL×2、飽和炭酸水素ナトリウム水溶液150mL、水150mL×2,飽和食塩水150mL×2の順で抽出・洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮し、黄色油状物を得た。別に、水層を酢酸エチル150mL×2、水150mL×2、飽和食塩水150mLの順で抽出・洗浄し、無水硫酸ナトリウムで乾燥後減圧濃縮することにより、少量の黄色油状物を回収した。一連の操作により、淡黄色油状物8.82gを得た。TLCにて確認を行ったところ、残渣には反応させた試薬等が残っていたことから、シリカゲルカラムクロマトグラフィーにより簡易精製(ヘキサン:酢酸エチル=1:1)を行い、白色結晶の1−(N−(t−ブトキシカルボニル)アミノ)−3−ベンジルオキシ−シクロブタン−1−カルボン酸エチルエステル 4.9282g(14mmol相当)を得た。
1−(N−(t−ブトキシカルボニル)アミノ)−3−ベンジルオキシ−シクロブタン−1−カルボン酸エチルエステル4.9282g(14mmol相当)にエタノール150mLを加えた後、パラジウム−活性炭素(パラジウム10%)900mgを加え、水素置換、室温下で一晩攪拌した。反応後、セライトを用いた濾過によりパラジウム−活性炭素を濾去し、濾液を減圧濃縮し、残渣として白色結晶5.74gを得た。ヘキサン:酢酸エチル=1:1(反応目的物のRf値=0.2付近)を展開溶媒として使用したTLC分析(UVとニンヒドリンによる呈色にて確認)にて反応追跡を行い、反応終了を確認した。次いで残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=1:1,ヘキサン:酢酸エチル=4:1) により分離精製し、白色結晶として1−(N−(t−ブトキシカルボニル)アミノ)−3−ヒドロキシ−シクロブタン−1−カルボン酸エチルエステル1.61g(6.2mmol相当)を得た。
なお、得られた1−(N−(t−ブトキシカルボニル)アミノ)−3−ヒドロキシ−シクロブタン−1−カルボン酸エチルエステルにつき、syn体の3位の炭素に結合しているトランス位のプロトンと、anti体の3位の炭素に結合しているシス位のプロトンとの1H−NMRの積分値からモル比を概算したところ、syn体とanti体との比は、14/46であった(図2)。
1−(N−(t−ブトキシカルボニル)アミノ)−3−ヒドロキシ−シクロブタン−1−カルボン酸エチルエステル259mg(1mmol、反応開始時のsyn/antiの比は、14/46)をピリジン4mLに溶解させ、氷浴下20分間攪拌した。無水トリフルオロメタンスルホン酸0.26mL(1.5mmol相当)を加え、そのまま30分間攪拌した。ヘキサン:ジエチルエーテル=1:1を展開溶媒(反応目的物のRf値=0.6付近)としたTLC分析(ニンヒドリンの呈色にて確認)を用いて反応を追跡し、反応終了を確認した。TLCでは、syn−1−(N−(t−ブトキシカルボニル)アミノ)−3−[((トリフルオロメチル)スルフォニル)オキシ]−シクロブタン−1−カルボン酸エチルエステルを表すRf値=0.4以外に原点にスポットが確認された(ヘキサン/ジエチルエーテル=1/1)。反応終了を確認後、反応液に水50mLとエーテル50mLを加え、1mol/L塩酸50mL×2、水50mL×2、飽和食塩水50mL×2の順で抽出洗浄した。無水硫酸ナトリウムで乾燥後、減圧濃縮することにより、淡黄色結晶297.2mgを得た。TLCにより、原点のスポットは消失しRf値=0.4以外にスポットは確認されなかった(ヘキサン/ジエチルエーテル=1/1)。反応残渣をシリカゲルカラムクロマトグラフィーにより分離精製(ヘキサン:ジエチルエーテル=3:1)することにより、白色結晶222.8mgをえた。NMRにより分析を行ったところ、syn−1−(N−(t−ブトキシカルボニル)アミノ)−3−[((トリフルオロメチル)スルフォニル)オキシ]−シクロブタン−1−カルボン酸エチルエステルであることが確認された。
1H−NMR(溶媒:CDCl3、共鳴周波数:500MHz):δ5.41−5.35(m, 1H),5.32(b,1H),4.26(q,2H,J=7 Hz),3.10−3.02(m, b,4H),1.45(s、9H),1.31(t,3H, J=7.0 Hz)
Claims (11)
- 前記反応工程において式(1)で表される化合物のOH基と反応して脱離基となる化合物が、直鎖又は分岐鎖の炭素数1から10のアルキルスルホン酸、直鎖又は分岐鎖の炭素数1から9のハロアルキルスルホン酸、芳香族スルホン酸、および芳香族スルホン酸クロライドからなる群より選ばれる一つまたは複数である請求項1の製造方法。
- アルキルスルホン酸が、メタンスルホン酸である請求項2の製造方法。
- ハロアルキルスルホン酸が、トリフルオロメタンスルホン酸である請求項2の製造方法。
- 芳香族スルホン酸が、トルエンスルホン酸、ニトロベンゼンスルホン酸、またはベンゼンスルホン酸である請求項2の製造方法。
- 芳香族スルホン酸クロライドが、トルエンスルホン酸クロライド、ベンゼンスルホン酸クロライド、またはニトロベンゼンスルホン酸クロライドである請求項2の製造方法。
- 前記反応工程における塩基が、直鎖又は分岐鎖の炭素数1から10の一級から三級のアルキルアミン、炭素数2から20の窒素含有複素環化合物、および炭素数2から20の窒素含有ヘテロ芳香族環化合物からなる群より選ばれる一つまたは複数である請求項1から6の何れか1項の製造方法。
- アルキルアミンが、エチルアミン、プロピルアミン、イソプロピルアミン、ジメチルアミン、ジエチルアミン、ジプロピルアミン、ジイソプロピルアミン、トリメチルアミン、トリエチルアミン、またはトリプロピルアミンである請求項7の製造方法。
- 窒素含有複素環化合物が、ピロリジン、イミダゾリン、ピラゾリジン、ピペリジン、ピペラジン、1,4−ジアザビシクロ[2.2.2.]オクタン、ピロリン、アジリジン、または1,8−ジアザビシクロ[5.4.0]ウンデカ−7−エンである請求項7の製造方法。
- 窒素含有ヘテロ芳香族環化合物が、ピロール、ピリジン、ピリミジン、ピラジン、トリアジン、イミダゾール、またはピラゾールである請求項7の製造方法。
- 前記精製工程が、分液精製法、カラム分離法、スラリー法、または再結晶法によるものである請求項1から10の何れか1項の製造方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008551038A JP5518337B2 (ja) | 2006-12-27 | 2007-12-17 | 放射性ハロゲン標識有機化合物の前駆体化合物の製造方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006351883 | 2006-12-27 | ||
JP2006351883 | 2006-12-27 | ||
PCT/JP2007/074220 WO2008078589A1 (ja) | 2006-12-27 | 2007-12-17 | 放射性ハロゲン標識有機化合物の前駆体化合物の製造方法 |
JP2008551038A JP5518337B2 (ja) | 2006-12-27 | 2007-12-17 | 放射性ハロゲン標識有機化合物の前駆体化合物の製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2008078589A1 true JPWO2008078589A1 (ja) | 2010-04-22 |
JP5518337B2 JP5518337B2 (ja) | 2014-06-11 |
Family
ID=39562382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008551038A Active JP5518337B2 (ja) | 2006-12-27 | 2007-12-17 | 放射性ハロゲン標識有機化合物の前駆体化合物の製造方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8563771B2 (ja) |
EP (2) | EP2128130B1 (ja) |
JP (1) | JP5518337B2 (ja) |
KR (1) | KR101408727B1 (ja) |
CN (1) | CN101573330B (ja) |
AU (1) | AU2007337481B2 (ja) |
BR (1) | BRPI0720465B8 (ja) |
CA (1) | CA2672914C (ja) |
HK (1) | HK1135372A1 (ja) |
NO (2) | NO345488B1 (ja) |
RU (1) | RU2466984C2 (ja) |
TW (1) | TWI402079B (ja) |
WO (1) | WO2008078589A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101608755B1 (ko) | 2005-11-29 | 2016-04-04 | 니혼 메디피직스 가부시키가이샤 | 방사성 할로겐 표식 유기 화합물의 전구체 화합물 |
EP2318332A1 (en) * | 2008-07-07 | 2011-05-11 | Bayer Schering Pharma Aktiengesellschaft | Process for production of radiopharmaceuticals |
AU2011335084B2 (en) | 2010-11-29 | 2015-08-20 | Ge Healthcare Limited | Preparation of pet precursor |
GB201021523D0 (en) | 2010-12-20 | 2011-02-02 | Ge Healthcare Ltd | Process simplification for precursor compound |
US9061977B2 (en) | 2010-12-20 | 2015-06-23 | Ge Healthcare Limited | Purification of precursor compound by crystallisation |
GB201021530D0 (en) * | 2010-12-20 | 2011-02-02 | Ge Healthcare Ltd | Purification of precursor compound by crystallisation |
BR112013020627B1 (pt) * | 2011-03-08 | 2019-12-03 | Ge Healthcare Ltd | processo para preparação de um composto |
GB201214220D0 (en) * | 2012-08-09 | 2012-09-19 | Ge Healthcare Ltd | Radiosynthesis |
CA3055417A1 (en) * | 2017-03-07 | 2018-09-13 | Nihon Medi-Physics Co., Ltd. | Radioactive fluorine-labeling precursor compound and method for producing radioactive fluorine-labeled compound using same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000500442A (ja) * | 1995-11-09 | 2000-01-18 | エモリー ユニバーシティ | 腫瘍画像化のためのアミノ酸アナログ |
JP2006510706A (ja) * | 2002-12-20 | 2006-03-30 | ジーイー・ヘルスケア・リミテッド | 18f−標識アミノ酸の固相製造 |
WO2006126410A1 (ja) * | 2005-05-23 | 2006-11-30 | Nihon Medi-Physics Co., Ltd. | 新規有機化合物及び該化合物を利用した放射性ハロゲン標識有機化合物の製造方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0115927D0 (en) * | 2001-06-29 | 2001-08-22 | Nycomed Amersham Plc | Solid-phase nucleophilic fluorination |
JP2004056725A (ja) * | 2002-07-24 | 2004-02-19 | Matsushita Electric Works Ltd | 設備管理サーバ、設備監視制御システムおよび設備管理サーバ用プログラム |
GB0422004D0 (en) | 2004-10-05 | 2004-11-03 | Amersham Plc | Method of deprotection |
JP5349960B2 (ja) | 2005-06-23 | 2013-11-20 | エモリー ユニバーシティー | 腫瘍画像化のためのアミノ酸類似体の立体選択的合成 |
KR101608755B1 (ko) | 2005-11-29 | 2016-04-04 | 니혼 메디피직스 가부시키가이샤 | 방사성 할로겐 표식 유기 화합물의 전구체 화합물 |
RU2434846C2 (ru) | 2006-05-11 | 2011-11-27 | Нихон Меди-Физикс Ко., Лтд. | Способ получения радиоактивного фтор-меченного органического соединения |
-
2007
- 2007-12-17 JP JP2008551038A patent/JP5518337B2/ja active Active
- 2007-12-17 AU AU2007337481A patent/AU2007337481B2/en active Active
- 2007-12-17 RU RU2009128664/04A patent/RU2466984C2/ru active
- 2007-12-17 KR KR1020097010950A patent/KR101408727B1/ko active IP Right Grant
- 2007-12-17 US US12/448,311 patent/US8563771B2/en active Active
- 2007-12-17 CN CN200780048213.XA patent/CN101573330B/zh active Active
- 2007-12-17 WO PCT/JP2007/074220 patent/WO2008078589A1/ja active Application Filing
- 2007-12-17 BR BRPI0720465A patent/BRPI0720465B8/pt active IP Right Grant
- 2007-12-17 EP EP07850708.4A patent/EP2128130B1/en active Active
- 2007-12-17 TW TW096148317A patent/TWI402079B/zh active
- 2007-12-17 NO NO20181508A patent/NO345488B1/no unknown
- 2007-12-17 EP EP18198896.5A patent/EP3530648B1/en active Active
- 2007-12-17 CA CA2672914A patent/CA2672914C/en active Active
-
2009
- 2009-06-23 NO NO20092389A patent/NO343437B1/no unknown
- 2009-12-24 HK HK09112138.9A patent/HK1135372A1/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000500442A (ja) * | 1995-11-09 | 2000-01-18 | エモリー ユニバーシティ | 腫瘍画像化のためのアミノ酸アナログ |
JP2006510706A (ja) * | 2002-12-20 | 2006-03-30 | ジーイー・ヘルスケア・リミテッド | 18f−標識アミノ酸の固相製造 |
WO2006126410A1 (ja) * | 2005-05-23 | 2006-11-30 | Nihon Medi-Physics Co., Ltd. | 新規有機化合物及び該化合物を利用した放射性ハロゲン標識有機化合物の製造方法 |
Non-Patent Citations (4)
Title |
---|
APPLIED RADIATION AND ISOTOPES, vol. 58(6), JPN6012014448, 2003, pages 657 - 666, ISSN: 0002415204 * |
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 42(3), JPN6012014449, 1999, pages 215 - 225, ISSN: 0002415206 * |
LAURENT MARTARELLO, J. MED. CHEM., vol. V45, JPN5005013395, 26 April 2002 (2002-04-26), pages 2250 - 2259, ISSN: 0002765374 * |
LIJUAN J. WANG ET AL, HETEROATOM CHEMISTRY, vol. 13, no. 1, JPN6012066735, 2002, pages 77 - 83, ISSN: 0002415205 * |
Also Published As
Publication number | Publication date |
---|---|
TW200826965A (en) | 2008-07-01 |
US8563771B2 (en) | 2013-10-22 |
NO343437B1 (no) | 2019-03-11 |
CA2672914C (en) | 2014-02-04 |
EP2128130B1 (en) | 2018-10-10 |
EP3530648B1 (en) | 2023-11-08 |
NO345488B1 (no) | 2021-03-01 |
TWI402079B (zh) | 2013-07-21 |
AU2007337481B2 (en) | 2012-02-09 |
EP2128130A1 (en) | 2009-12-02 |
US20100016626A1 (en) | 2010-01-21 |
KR20090093969A (ko) | 2009-09-02 |
CN101573330B (zh) | 2015-04-08 |
RU2009128664A (ru) | 2011-02-10 |
NO20092389L (no) | 2009-09-21 |
KR101408727B1 (ko) | 2014-06-17 |
BRPI0720465B1 (pt) | 2018-11-27 |
RU2466984C2 (ru) | 2012-11-20 |
JP5518337B2 (ja) | 2014-06-11 |
CN101573330A (zh) | 2009-11-04 |
CA2672914A1 (en) | 2008-07-03 |
NO20181508A1 (no) | 2009-09-21 |
AU2007337481A1 (en) | 2008-07-03 |
HK1135372A1 (en) | 2010-06-04 |
EP3530648A1 (en) | 2019-08-28 |
BRPI0720465A2 (pt) | 2014-01-14 |
EP2128130A4 (en) | 2012-01-04 |
WO2008078589A1 (ja) | 2008-07-03 |
BRPI0720465B8 (pt) | 2021-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5518337B2 (ja) | 放射性ハロゲン標識有機化合物の前駆体化合物の製造方法 | |
JP5684333B2 (ja) | 放射性ハロゲン標識有機化合物の製造方法 | |
JP4550141B2 (ja) | 放射性フッ素標識有機化合物の製造方法 | |
JP5732198B2 (ja) | 放射性フッ素標識有機化合物の製造方法 | |
JPWO2006126410A1 (ja) | 新規有機化合物及び該化合物を利用した放射性ハロゲン標識有機化合物の製造方法 | |
JP6018578B2 (ja) | Pet前駆体の製造 | |
JP4997463B2 (ja) | ピリジン酸化型化合物、並びに、これを用いたカルボン酸誘導体及びその光学活性体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101013 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130321 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140203 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140212 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140402 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5518337 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |